The Annual General Meeting of Active Biotech was held on May 22, 2024. The following main resolutions were passed.In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2023, and that the Company’s accumulated loss shall be carried forward.…
FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 22, 2024 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…
In accordance with a decision made by the Annual General Meeting held on May 24, 2023, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2023, and the Chairman of the Board. If a shareholder does not exercise its right…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
The Annual General Meeting of Active Biotech was held on May 24, 2023. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2022, and that the Company’s accumulated loss shall be carried…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 24, 2023 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2022, and the Chairman of the Board. If a shareholder does not exercise its right…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The…
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting…
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board. If a shareholder does not exercise its right…
PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 19, 2021. Due to the extraordinary situation as a result of the COVID-19 pandemic, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board…
Active Biotech’s Annual Report 2020 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 22, 2021 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO,…
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 19, 2021. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW …
PRESS RELEASE, Lund Sweden, December 1, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) In accordance with a decision made by the Annual General Meeting held on May 19, 2020, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2020, and…
An extraordinary general meeting of Active Biotech was held on November 30, 2020. The meeting resolved, in accordance with the board’s proposal, on a new share issue with pre-emptive rights for existing shareholders. Through the rights issue, not more than 72,618,240 new shares are issued. Two existing shares entitle to…
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Tuesday, May 19, 2020, at 5 p.m. in the Company’s offices, Scheelevägen 22 in Lund, Sweden. INFORMATION RELATING TO THE CORONA VIRUSAs a…
PRESS RELEASE Lund Sweden, February 5, 2020 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that the Board of Directors, has approved a new direction for the company. This decision follows a detailed opportunity analysis of the company’s wholly owned clinical lead assets, laquinimod and tasquinimod. Based on assessment of the…
PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 23, 2019. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid. The members of the Board and the President were discharged from liability with respect to their management of…
PRESS RELEASE The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 23, 2019, at 5 pm at the company’s offices, Scheelevägen 22 in Lund, Sweden. Please see the attached notification, which is being…
PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 17, 2018. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid. The board members and the managing director were discharged from liability with respect to their management of the…
The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 17, 2018, at 5 pm at the company’s offices, Scheelevägen 22 in Lund, Sweden. Please see the attached notification, which is being announced within…
PRESS RELEASE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. Extraordinary General Meeting of Active Biotech was held on March 19, 2018. The meeting…
PRESS RELEASE The Annual General Meeting of Active Biotech was held on June 15, 2017. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid. The board members and the managing director were discharged from liability with respect to their management of the…
Active Biotech’s Annual Report 2016 is now available för download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, May 18, 2017 Tomas LeandersonPresident & CEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46 192044 About Active BiotechActive Biotech…
The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, June 15, 2017, at 5 pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden. Please see the attached notification, which is being announced within…
